# US 2013/0253178 A1 · 2'-o-modified rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253178 A1
- Document ID: US20130253178A1
- Status: Published application
- Kind: A1
- Application number: 13/990,441
- Filed: 2011-11-28
- Published: 2013-09-26
- Earliest claimed: 2010-11-30
- Assignees: The University of Tokyo; Chiralgen, Ltd.
- Inventors: Mamoru Shimizu; Takeshi Wada; Kouichiro Arai
- Web page: https://patentgrep.com/patent/US20130253178A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- C07H 1/00: Processes for the preparation of sugar derivatives
- C07H 19/06: Pyrimidine radicals
- C07H 19/067: with ribosyl as the saccharide radical
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/167: with ribosyl as the saccharide radical
- C07H 23/00: Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12 (esters with inorganic acids C07H11/00)
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

[Problem] To provide a 2′-modified ribonucleoside or the like which has a high duplex-forming ability. [Solution] The present invention is generally based on the finding in embodiments that a modified form of a ribonucleoside or the like having an alkoxymethyl protective group can be imparted with a high duplex-forming ability by introducing, as a substituent, a halogen atom into the protective group moiety. As explained before, a modified form of RNA having an alkoxymethyl protective group has a low duplex-forming ability. A modified form of RNA having a halogen-substituted alkoxymethyl protective group, however, exhibits a high duplex-forming ability that is comparable to the duplex-forming ability of a 2′-O-methyl modified nucleic acid.

## Claims

### Claim 1

A ribonucleoside, a ribonucleotide, or a derivative thereof having a protective group at the 2′-position, wherein the protective group is represented by the following Formula (I).
In the formula, O* represents an oxygen atom of the hydroxyl group at the 2′ position of the ribonucleoside, the ribonucleotide, or the derivative thereof,
R1 and R2 may be identical or different, and each represents a hydrogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, or a C1-3 haloalkyl group,
R3 and R4 may be identical or different, and each represents a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, or a C1-3 haloalkyl group,
R5 and R6 may be identical or different, and each represents a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, a C1-3 haloalkyl group, a C1-3 alkyl group substituted with one or two C6-12 aryl groups, or a C6-12 aryl group optionally having a substituent, and
R7 represents a halogen atom or a C1-3 haloalkyl group.

### Claim 2 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1,
wherein R′ to R4 may be identical or different, and each represents a hydrogen atom, a methyl group or an ethyl group,
R5 and R6 may be identical or different, and each represents a hydrogen atom, a halogen atom, or a C1-3haloalkyl group, and
R7 represents a halogen atom.

### Claim 3 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1,
wherein all of R1 to R4 represent a hydrogen atom,
R5 and R6 may be identical or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or a bromine atom, and
R7 represents a fluorine atom, a chlorine atom or a bromine atom.

### Claim 4 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1,
wherein all of R1 to R5 represent a hydrogen atom,
R6 represents a hydrogen atom, a fluorine atom or a chlorine atom, and
R7 represents a fluorine atom or a chlorine atom.

### Claim 5 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1,
wherein all of R1 to R5 represent a hydrogen atom,
R6 represents a hydrogen atom, or a chlorine atom, and
R7 represents a chlorine atom.

### Claim 6 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1, which is
2′-O-(2-chloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2-dichloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2,2-trichloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2-difluoro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2,2-trifluoro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2-chloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B,
2′-O-(2,2-dichloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B,
2′-O-2,2,2-trichloroethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B,
2′-O-2,2-difluoroethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B,
2′-O-2,2,2-trifluoroethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B,
2′-O-(2-chloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2,2-dichloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2,2,2-trichloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2,2-difluoro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2,2,2-trifluoro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2-bromo)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2-dibromo)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2,2,2-tribromo)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,
2′-O-(2-bromo)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite),
2′-O-(2,2-dibromo)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite), or
2′-O-(2,2,2-tribromo)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite) when the nucleic acid base B is adenosine, guanosine, cytidine or uridine.

### Claim 7 (depends on 1)

The ribonucleoside, the ribonucleotide, or the derivative thereof having a protective group at the 2′-position according to claim 1, which is
2′-O-(2-chloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite), or
2′-O-(2,2-dichloro)ethoxymethyl-5′-O-(4,4′-dimethoxytrityl)nucleic acid base B 3′-(2-cyanoethyldiisopropyl phosphoramidite) when the nucleic acid base B is adenosine, guanosine, cytidine or uridine.

### Claim 8

A method of manufacturing a ribonucleoside, a ribonucleotide, or a derivative thereof represented by the following Formula (I) and having a protective group at the 2′-position, the method comprising:
a process of reacting a compound represented by the following Formula (III) with a compound represented by the following Formula (II).
(In Formula (I), O* represents an oxygen atom of a hydroxyl group at the 2′ position of the ribonucleoside, the ribonucleotide, or the derivative thereof,
R1 and R2 may be identical or different, and each represents a hydrogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, or a C1-3 haloalkyl group,
R3 and R4 may be identical or different, and each represents a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, or a C1-3 haloalkyl group,
R5 and R6 may be identical or different, and each represents a hydrogen atom, a halogen atom, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, a hydroxy C2-3 alkyl group, a C1-3 haloalkyl group, a C1-3 alkyl group substituted with one or two C6-12 aryl groups, or a C6-12 aryl group optionally having a substituent, and
R7 represents a halogen atom or a C1-3 haloalkyl group.)
(In Formula (II), B represents a nucleic acid base that may be protected with a protective group, R21, R22, R23 and R24 may be identical or different, and each represents a C1-5 alkyl group, a C1-5 alkoxy group or a C1-5 haloalkyl group that may be straight or branched, and R1 and R2 represent the same as R1 and R2 in Formula (I).)
(In Formula (III), R3 to R7 represent the same as R3 to R7 in Formula (I).)

### Claim 9 (depends on 8)

The method of manufacturing a ribonucleoside, a ribonucleotide, or a derivative thereof having a protective group at the 2′-position according to claim 8, further comprising:
a process of reacting a compound represented by Formula (III) with a compound represented by Formula (II) to obtain a compound represented by the following Formula (IV), and then reacting the compound represented by Formula (IV) with a C1-3 alcohol to obtain a compound represented by the following Formula (V); and
a process of reacting the compound represented by Formula (V) with dimethoxytriphenylmethyl halide, to obtain a compound represented by Formula (VI).
(In Formula (IV), B represents a nucleic acid base that may be protected with a protective group, R1 to R7 represent the same as R1 to R7 in Formula (I), and R21 to R24 represent the same as R21 to R24 in Formula (II).)
(In Formula (V), B represents a nucleic acid base that may be protected with a protective group, and R1 to R7 represent the same as R1 to R7 in Formula (I).)
(In Formula (VI), B represents a nucleic acid base that may be protected with a protective group, R1 to R7 represent the same as R1 to R7 in Formula (I), and the formula DMTr represents a 4,4′-dimethoxytrityl group.)

### Claim 10 (depends on 9)

The method of manufacturing a ribonucleoside, a ribonucleotide, or a derivative thereof having a protective group at the 2′-position according to claim 9, further comprising, after the process of obtaining the compound represented by Formula (VI):
a process of reacting the compound represented by Formula (VI) with a compound represented by the following Formula (VII) to obtain a compound represented by the following Formula (VIII).
(Formula (VII),
R31 to R34 may be identical or different, and each represents a hydrogen atom, a C1-3 alkyl group, or a C1-3 haloalkyl group,
R35 and R36 may be identical or different, and each represents a C1-5 alkyl group or a C1-5 haloalkyl group, and
R37 represents a halogen atom.)
(In Formula (VIII), B represents a nucleic acid base that may be protected with a protective group, R1 to R7 represent the same as R1 to R7 in Formula (I), R31 to R36 represent the same as R31 to R36 in Formula (VII), and the formula DMTr represents a 4,4′-dimethoxytrityl group.)
